West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
According to recent survey by Medicomp Systems, 43 percent of healthcare IT professionals and physicians cited that their top data-related challenge was not a lack of data but rather the struggle to access the right data at the right time. Those findings aren't surprising since the vast majority of health information systems today share a common design flaw: they don't think and work the way physicians do at the point of care. However, they are still deeply concerning.
To deliver the best patient care, physicians need clinically relevant data that is seamlessly presented within their current workflows and integrated into the same workspace. The result is not only better patient care and better outcomes but also higher clinical effectiveness, efficiency, and satisfaction.
To view the multimedia release go to:
https://www.multivu.com/players/English/8189651-medicomp-systems-ebook-healthcare-data-challenges/
The most detailed analysis yet of the role germline mutations in genes associated with cancer predisposition play in the development of childhood cancer suggests that comprehensive genomic screening may be warranted on all pediatric cancer patients, not just those with a family history of cancer. The study from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project appears in the November 19 edition of the New England Journal of Medicine.
Ultimately, researchers anticipate that systematic monitoring of patients and family members who have germline mutations in cancer predisposition genes will allow the detection of cancers at their earliest and most curable stage, thereby improving the outcomes for these children and family members.
To view the multimedia release go to:
http://www.multivu.com/players/English/7692851-st-jude-hospital-genome-project/
As millions of Americans begin choosing a health plan for the first time under the Affordable Care Act, the new Healthgrades American Hospital Quality Outcomes 2014: Report to the Nation released today reveals how hospital selection can dramatically impact a patient’s health. The report demonstrates that individuals are far more likely to die or suffer complications at hospitals receiving the lowest Healthgrades rating. In fact, each year an estimated 234,252 lives could potentially be saved and 157,418 complications could be avoided if all hospitals performed similarly to the highest rated hospitals.
To view Multimedia News Release, go to http://www.multivu.com/mnr/63942-healthgrades-american-hospital-quality-outcomes-2014-report-to-the-nation
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
We are technocrats specialized mainly in plastic pyrolysis and have successfully developed pyrolysis technology by providing positive outcomes to our clients! Visit our website http://www.zorbaindustries.com/
Cancer takes more children’s lives than any other disease in the U.S., and nearly 25,000 kids will be diagnosed during the month of September alone. As the largest private funder of childhood cancer research grants, the St. Baldrick’s Foundation is on a mission to take childhood back from cancer by raising critical dollars for lifesaving research and spreading awareness about the harsh realities of childhood cancer.
This September, in recognition of Childhood Cancer Awareness Month, St. Baldrick’s will show how the research it funds is accelerating the development of new therapies and cures for kids with cancer everywhere. The Foundation will also share stories of kids affected by cancer – kids like David and Hazel who were both diagnosed with neuroblastoma, but faced two different outcomes.
To view the multimedia release go to:
https://www.multivu.com/players/English/7916553-st-baldricks-childhood-cancer-awareness-month/
BloodCenter of Wisconsin’s Diagnostic Laboratories, part of Versiti, today announced the launch of seven hematology genetics test panels. The new test panels enhance and expand BloodCenter’s genetic testing capability to include a vast array of non-malignant hematology disorders, including platelet function disorders, inherited thrombocytopenia and congenital neutropenias, providing one of the most comprehensive test menus in hematology.
BloodCenter’s integration of functional and genetic testing provides a unique approach to diagnosing complex hematology disorders, providing a comprehensive review of each patient for improved patient care and outcomes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8126851-bloodcenter-of-wisconsin-versiti-hematology-genetics-test-panels/
